

## Original Research Article

# Candiduria in high-risk patients and its antifungal susceptibility testing

Mayuri P. Shetty\*, Jayshree B. Bhakre, Jyoti A. Iravane

Department of Microbiology, Government Medical College and Hospitals, Aurangabad, Maharashtra, India

**Received:** 27 June 2024

**Revised:** 12 August 2024

**Accepted:** 13 August 2024

### \*Correspondence:

Dr. Mayuri P. Shetty,

E-mail: mayurishetty33@gmail.com

**Copyright:** © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

## ABSTRACT

**Background:** Candida is part of the natural microbiota of an individual's mouth cavity, gastrointestinal system, and vagina. Candida species are of clinical importance because they are the most common cause of nosocomial urinary tract infections (UTIs), oral candidiasis, and genitourinary candidiasis. The presence of budding yeast cells in urine can be a sign of extensive candidiasis, urinary tract infections, or sample contamination. It is necessary to confirm the presence of yeast cells in a fresh urine sample to differentiate contamination from colonization or infection. Numerous antifungals are available to treat candida infections. Over the last few decades, there has been an increase in antifungal resistance, especially against non-albicans species.

**Methods:** A hospital-based retrospective observation study was conducted over 12 months, from January 2023 to December 2023 in department of microbiology at Government Medical College and Hospital Aurangabad (Chhatrapati Sambhajanagar), Maharashtra. A total of 2434 samples were received and processed according to standard operating procedures.

**Results:** A total of 38 (26.76%) *C. albicans* and 104 (73.23%) non-albicans species were isolated from 142 urine samples. *C. tropicalis* was the most frequently isolated *Candida* species (52.11%) from urine cultures, followed by *C. albicans* (26.76%), *C. glabrata* (8.45%), *C. parapsilosis* (7.04%), *C. krusei* (2.8%), and *C. guilliermondii* (2.8%). All *Candida* species were maximally susceptible to fluconazole, itraconazole, caspofungin, and voriconazole as compared to amphotericin B and ketoconazole.

**Conclusions:** The finding of candiduria in a patient with or without symptoms should be neither neglected nor hastily managed but requires a careful evaluation that should proceed in a logical manner.

**Keywords:** Antifungal susceptibility, Candida species, Candiduria, Non-albicans

## INTRODUCTION

Candida species are naturally present on the skin, gut, and genital tract. It can cause several infections. The presence of yeast cells in the urine is referred to as candiduria.<sup>1,2</sup>

Urinary candidiasis is one of the most challenging forms of candidiasis because distinguishing between colonization and true infection is difficult. Candiduria may also indicate candidemia or invasive renal candidiasis.<sup>1,3</sup>

Candiduria is linked to many predisposing factors, including the use of indwelling urinary catheters, diabetes, antibiotic use, immunosuppressive medication, impaired kidney function, extremes of age, and female gender.<sup>1,2,4-6</sup> Candiduria, when not appropriately detected and treated, has caused morbidity and mortality while inappropriate management leads to overtreatment which causes the development of drug resistance.<sup>2,6,7</sup>

So, the current study was conducted to know the incidence of candida species causing UTIs and their antifungal susceptibility pattern in a tertiary care hospital.

## METHODS

A hospital-based retrospective study was conducted over 12 months, from January 2023 to December 2023 in Department of Microbiology at Government Medical College and Hospital Aurangabad (Chhatrapati Sambhajanagar), Maharashtra. A total of 2434 aseptically collected urine samples were received in tertiary care hospital. Data analysis was done by statistical method with statistical software SPSS ver.2022. Since this was a retrospective study ethical approval was not needed.

### Inclusion criteria

Urine samples showing yeast cells or pseudo hyphae on wet mount examination. Pure growth of yeast isolates showing a significant colony count  $>105$  CFU/ml in non-catheterized patients and  $>103$  in catheterized patients. Patients with associated risk factors such as age, gender, diabetes, hospital stay, kidney diseases, use of broad-spectrum antibiotics, and indwelling urinary tract catheters were also considered.

### Exclusion criteria

Sample showing mixed growth of microorganisms on culture.

### Procedure methodology

The urine samples were centrifuged, and the sediment was analyzed using microscopy, Gram staining, and culture. A wet-mount examination of the urine sample was performed to look for pus cells, RBCs, budding yeast cells, pseudo hyphae, cast, crystals, etc.

Urine samples were cultured on cysteine lactose electrolyte deficient (CLED) agar by using a calibrated loop as per the standard protocol of urine culture. On the same day, samples showing yeast cells or pseudo hyphae on microscopy were cultured on Sabouraud dextrose agar (SDA) with chloramphenicol (0.05 mg/ml). The inoculated culture plates were incubated at 37°C for 24-48 hours.<sup>2</sup>

Samples showing significant colony count and pure growth of yeast cells on culture were processed according to standard operating procedures.

The identification process involved observing colony morphology on SDA, performing Gram stain and germ tube tests, using CHROM agar, carrying out Dalmau culture on corn meal agar, and utilizing VITEK-2 cards (ID cards).

Candiduria was confirmed by the presence of budding yeast cells, pseudo hyphae on wet mount examination, and pure growth of yeast cells on culture with a significant colony count.

### Antifungal susceptibility test (AFST)

Candida isolates were subjected to AFST using the disc diffusion method on Mueller Hinton agar containing 2% glucose and 0.5 µg/ml of methylene blue, according to CLSI standards (M-44A2).

The plates were incubated aerobically at 37°C for 24-48 hours. The zone of inhibition was measured according to the standard protocol.

The antifungal susceptibility test was performed using commercially available antifungal discs (Hi-media). fluconazole (25µg), itraconazole (10 µg), ketoconazole (10 µg), amphotericin B (20 µg), caspofungin (5 µg), voriconazole (1µg).

### Quality control

The sterility of each batch of media prepared was checked by incubating at 37°C for 24 hours. *Candida albicans* American type culture collection (ATCC) 90028 was used as a quality control strain for the antifungal susceptibility testing.



Figure 1: Urine wet mount showing budding yeast cells.




Figure 2: Gram stain showing gram positive budding yeast cells.



**Figure 3: Candida species on hichrome.**



**Figure 4: Dalmau technique on corn meal agar.**

## RESULTS


A total of 2434 urine samples were received in tertiary care hospitals. Out of which, 236 samples showed budding yeast cells on wet-mount examination (Figure 1). 142/236 urine samples showed pure growth of yeast cells on culture media with a significant colony count.

A total of 104 (73.23%) non-albicans and 38 (26.76%) *C. albicans* species were isolated from 142 culture-positive urine samples. *C. tropicalis* (52.11%) was the most frequently isolated Candida species from urine cultures, followed by *C. albicans* (26.76%), *C. glabrata* (8.45%), *C. parapsilosis* (7.04%), *C. krusei* (2.8%), and *C. guilliermondii* (2.8%) (Figure 7).


**Table 1: Risk factors associated with candiduria.**

Risk factor	No. of cases
Male	58
Female	84
Age >45 years	82
Antibiotic therapy	98
Catheterization	93
Diabetes mellitus	68
Prolonged hospital stay	90

When we looked at the risk factors associated with urinary candidiasis, we observed that antibiotic medication (69%) and catheterization (65.4%) were the most common risk factors for UTIs caused by Candida infection (Table 1).




**Figure 5: Male female ratio.**



**Figure 6: Age-wise distribution of candida isolates.**

Candida isolation rates were more in female (Figure 5) and more common in the age group over 45 years (Figure 6).



**Figure 7: Species-wise distribution of Candida isolates.**

*Candida albicans* were maximally susceptible to caspofungin (92.10%), and voriconazole (92.10%) as compared to amphotericin B (68.42%) and ketoconazole (39.47%) (Figure 8).

Similarly, also non-albicans were maximally susceptible to caspofungin (91.25%), and voriconazole (89.58%) as compared to amphotericin B (72.76%) and ketoconazole (49.04%) as shown in Figure 9.

Increase in resistance to fluconazole (11.2%) was also noticed among non-albicans candida than *C. albicans* (6.26%).

#### AFST profile of *C. albicans*

Figure 8 shows percentage of antifungal susceptibility of *C. albicans*. *C. albicans* were highly susceptible to voriconazole and caspofungin but less susceptible to ketoconazole and amphotericin B.

#### AFST profile for Non-albicans candida

Figure 9 shows percentage of antifungal susceptibility of non-albicans. Non-albicans were highly susceptible to voriconazole and caspofungin but less susceptible to ketoconazole and amphotericin B.




Figure 8: Susceptibility pattern in *C. albicans*.




Figure 9: Susceptibility pattern in non- albicans candida.

## DISCUSSION

Nosocomial candidal UTI is rapidly gaining importance in tertiary care facilities. Identifying whether candiduria

is due to urinary tract infections, bladder colonization, or contamination is a common clinical issue.<sup>1</sup> Most cases of candiduria are considered benign asymptomatic infections but may be associated with candidemia and renal infection. Candiduria could result in pyelonephritis or disseminated infection.<sup>3,8</sup>

In the present study, the isolation rate of *Candida* species from urine samples was 5.8%, which is slightly higher than the observations of the Agrawal et al study (3.51%) but similar to the study by Goel et al (5.77%) Mahajan et al (5.4%).<sup>4,9,10</sup> The candida isolation rate was slightly higher in a study by Shrestha et al (7.7%).<sup>11</sup> The study suggests the most frequent yeasts isolated from urine cultures were non-albicans. Among the non-albicans, *C. tropicalis* was the most commonly isolated species, which was a similar finding to the study by Gupta et al.<sup>12</sup> In this study, the most common risk factors associated with candiduria were catheterization and antibiotic therapy, which was similar to the Manisha et al study.<sup>5</sup> The present study had a slight female preponderance, which was a similar finding to the study of Abhishek et al and Ekpo et al.<sup>2,3</sup> In this study, antifungal fluconazole, itraconazole, and voriconazole were all equally effective against all *Candida* species, which was a similar finding to the study by Singh et al.<sup>13</sup>

The study limitation was the lack of genomic characterization of isolates. The study also lacks an assessment of the virulence factors of different candida species.

## CONCLUSION

In this study, non-albicans were among the most often isolated yeasts. Non-albican *Candida* are more resistant to antifungal agents than *C. albicans*. So, before starting antifungal treatment, it is essential to know the candida species. (For example, *C. krusei* is intrinsically resistant to fluconazole and *C. lusitanae* to amphotericin B).

In the conducted study, we have gained a clear understanding of the predisposing factors of candiduria, the common species of *Candida* isolated, and their susceptibility to commonly used antifungal drugs.

The diagnosis of candiduria in a patient with or without symptoms should be neither neglected nor hastily managed but requires a careful evaluation that should proceed logically.

**Funding:** No funding sources

**Conflict of interest:** None declared

**Ethical approval:** Not required

## REFERENCES

1. Reshmi C, Nautiyal S, Maheswari B. Candiduria: current scenario. IOSR J Pharm. 2015;5(4):16-9.



2. Ekpo IA, Kechia FA, Iwewe YS, Ngueguim AD, Nangwat C, Dzoyem JP. Species distribution and antifungal susceptibility profile of *Candida* spp. isolated from urine of hospitalized patients in Dschang District Hospital, Cameroon. *Int J Biol Chem Sci.* 2017;11(3):1212-21.
3. Abishek VC, Mohanram K, Preethy R. Prevalence of candiduria and characterisation of *Candida* species in tertiary care center. *Saudi J Pathol Microbiol.* 2019;4(7):573-6.
4. Goel R, Singh S, Gill AK, Kaur A, Kour I. Speciation, characterization and antifungal susceptibility pattern of *Candida* species. *Int J Contemp Med Res.* 2018;5(5):E1-4.
5. Jain M, Dogra V, Mishra B, Thakur A, Loomba PS, Bhargava A. Candiduria in catheterized intensive care unit patients: emerging microbiological trends. *Indian J Pathol Microbiol.* 2011;54(3):552-5.
6. Yashavanth R, Shiju MP, Bhaskar UA, Ronald R, Anita KB. Prevalence of *Candida* species among uropathogens and their antifungal susceptibility pattern in a tertiary care hospital. *J Clin Diagn Res.* 2013;7:2459-61.
7. Jacobs DM, Dilworth TJ, Beyda ND, Casapao AM, Bowers DR. Overtreatment of asymptomatic candiduria among hospitalized patients: a multi-institutional study. *Antimicrob Agents Chemother.* 2018;62(1):10-128.
8. Prakash V, Verma D, Agarwal S. Candiduria: its characterization, antifungal susceptibility pattern and biofilm formation. *Int J Res Med Sci.* 2018;6(12):4070-6.
9. Agrawal A, Shah H, Tada D, Vegad MM, Pipaliya B, Sathwara N. Prevalence of *Candida* and its antifungal susceptibility in patients of urinary tract infections. *Nat J Integr Res Med.* 2017;8(2).
10. Mahajan A, Kaur N, Kaur A, Singh S, Gill A. Isolation, identification, and antifungal susceptibility pattern of *Candida* spp. isolated from UTI cases in a tertiary care hospital. *Sch J App Med Sci.* 2015;3(5E):2146-52.
11. Shrestha S, Bhandari N, Gopali B, Pandey B, Thapa P, Shrestha B, et al. Candiduria in the patients visiting at Kathmandu Model Hospital, Nepal. 2024.
12. Gupta J, Shah H. Isolation, speciation and antifungal drug susceptibility of *Candida* species from clinically suspected infections in a tertiary care hospital. *Trop J Pathol Microbiol.* 2016;2:183-91.
13. Singh Y, Karicheri R, Nath D. The burden of catheter associated urinary tract infection by *Candida Albicans* and non *Albicans* with emphasis on biofilm formation and antifungal sensitivity pattern. *Int J Health Sci.* 2022(II):2356-63.
14. Nademi A, Shahrokh H, Kordbacheh P, Zaini F, Rezaie S, Mahmoudi M, et al. Identification and antifungal susceptibility pattern of *Candida* species isolated from patients with nosocomial candiduria. *J Mycol Res.* 2015;2(2):77-84.
15. Rishi S, Jain B, Ruchi VN. Prevalence of *albicans* and non-*albicans* candiduria in a tertiary care hospital of Jaipur, India. *Galore Int J Health Sci Res.* 2020;5(1):1-5.
16. Ragini A, Sandhya B, Gayatridevi I. Characterisation and antifungal susceptibility testing for *Candida* in tertiary care hospital. *J Health Sci Res.* 2011;2(2):1-2.
17. Ponnambath DK, Swaran KM, Boppe A, Shanmugam K. Clinico-mycological and antifungal susceptibility profiles of candiduria in a tertiary care hospital from southern India. *Nat J Lab Med.* 2017;6(4):7-12.
18. Jain S, Ahmad N, Tomar S. Epidemiology, characterization and antifungal susceptibility profile of *Candida* species isolated from suspected cases of urinary tract infections at tertiary care centre of North Delhi. *Int J Health Sci Res.* 2020;10(6):286-90.
19. Hassaneen AM, Ghonaim RA, Hassanin HM, Salama NA, Elgohary TA. Different aspects of candiduria as an important nosocomial infection. *Med J Cairo Univ.* 2014;82(1):199-204.
20. Prasanna S, Partha R, Puneet B. Identification and antifungal susceptibility profile of *Candida* isolates. *Int J Curr Microbiol Appl Sci.* 2016;5(3):579-89.
21. Joshi E, Najotra DK, Singh VA. Prevalence and risk factors of nosocomial candiduria-a one-year prospective study from a tertiary care centre of Haryana, India. *International Journal of Current Microbiology and Applied Sciences,* 2015;4(10):402-8.
22. Pramodhini S, Srirangaraj S, Easow JM. Candiduria-study of virulence factors and its antifungal susceptibility pattern in tertiary care hospital. *J Lab Phys.* 2021;13(3):231-7.
23. Ghasemi R, Rabiei MM, Lotfali E, Abolghasemi S, Ansari S. Candiduria: prevalence, identification of isolated *Candida* species and trends in antifungal susceptibility in hospitalized patients. *Novel Biomed.* 2020;8(2):71-6.
24. Sardi JC, Scorzoni L, Bernardi T, Fusco-Almeida AM, Mendes Giannini MJ. *Candida* species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. *J Med Microbiol.* 2013;62(1):10-24.

**Cite this article as:** Shetty MP, Bhakre JB, Iravane JA. Candiduria in high-risk patients and its antifungal susceptibility testing. *Int J Res Med Sci* 2024;12:3310-4.